Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantum Computing and Quantum Technologies in Drug Discovery and Therapeutics: Evidence, Benchmarking, and Translational Integration.

Drug design, development and therapy·2026
Same author

Therapeutic Alternatives to Recombinant Biologics: Mechanistic Framework, Clinical Evidence, and Selection Guidance.

Drug design, development and therapy·2026
Same author

Quantum mechanics in drug design: Progress, challenges, and future frontiers.

Communicative & integrative biology·2025
Same author

Artificial Intelligence in Small-Molecule Drug Discovery: A Critical Review of Methods, Applications, and Real-World Outcomes.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

Engineering Universal Cancer Immunity: Non-Tumor-Specific mRNA Vaccines Trigger Epitope Spreading in Cold Tumors.

Vaccines·2025
Same author

Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025).

Pharmaceutics·2025

Related Experiment Videos

A Risk-Tiered Validation Framework for Artificial Intelligence in Drug Discovery: From Reproducibility to Clinical

Sarfaraz K Niazi1

  • 1College of Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA.

International Journal of Molecular Sciences
|May 27, 2026
PubMed
Summary

Artificial intelligence (AI) in drug discovery now models complex protein dynamics, but validation is the new bottleneck. A four-tier framework is proposed to match evidence standards with AI application risks in molecular sciences.

Keywords:
artificial intelligencecomputational chemistrydrug discoveryensemble predictionlifecycle governancemachine learningmodel-informed drug developmentmolecular dynamicsmolecular sciencesprotein–ligand predictionregulatory scienceuncertainty quantificationvalidation

Related Experiment Videos

Area of Science:

  • Molecular sciences, computational chemistry, and drug discovery.
  • Focus on artificial intelligence (AI) and machine learning (ML) applications in predicting molecular behavior and drug efficacy.

Background:

  • AI has evolved from static protein structure prediction to modeling dynamic conformational ensembles and binding affinities.
  • Recent foundation models (e.g., BioEmu, AlphaFlow) address prior AI limitations in drug discovery, but many require peer-reviewed validation.
  • The primary challenge in AI drug discovery has shifted from data representation to rigorous validation of AI-generated predictions.

Purpose of the Study:

  • To introduce a four-tier validation framework for AI applications in molecular sciences.
  • To align computational and experimental evidence with translational and regulatory risks.
  • To guide the assessment of AI/ML models used in drug discovery pipelines.

Main Methods:

  • Development of a four-tier validation hierarchy: Tier 1 (internal reproducibility), Tier 2 (benchmark robustness), Tier 3 (prospective experimental validation), and Tier 4 (clinical/translational calibration).
  • Integration of principles from ICH guidelines, FDA's MIDD, EMA's AI reflection paper, and the EU AI Act.
  • Inclusion of recent evidence from ensemble-aware AI, prospective docking, free-energy calculations, and clinical-stage AI candidates.

Main Results:

  • The proposed framework categorizes AI applications (sequence, structure, ensemble, complex, trajectory analysis) into validation tiers.
  • It emphasizes the need for evidentiary standards to keep pace with AI prediction generation and application.
  • The framework provides a conceptual guide, not a regulatory mandate, for AI validation.

Conclusions:

  • A significant shift is occurring from AI representation challenges to validation difficulties in drug discovery.
  • Robust validation frameworks are crucial to manage the risks associated with rapidly advancing AI technologies.
  • Recommendations are provided for lifecycle governance, uncertainty reporting, and harmonized evidentiary templates for AI/ML in molecular sciences.